Skin and Soft Tissue Infection Treatment Market: Overview
Skin and soft tissue infections (SSTIs)
are one of the most common infections present in inpatient as well as
outpatients. Skin and soft tissue infections (SSTIs) comprise of various
minor and major infections of skin, fascia, subcutaneous tissue and
muscle. These infections include such as impetigo, folliculitis,
furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and
pyomyositis. These infections may be associated with an underlying
cause such as diabetes or systemic immunosuppression.
Skin and soft tissue infections (SSTIs)
may be caused by any of the pathogenic microorganisms which include
Staphylococcus aureus, Streptococcus pyogene, gram-negative bacilli,
Pseudomonas aeruginosa, beta-hemolytic streptococci, Enterococcus,
streptococci, staphylococci, Peptostreptococcus, Bacteroides,
Clostridium and S. pyogenes. Methicillin-resistant Staphylococcus aureus
(MRSA) and streptococci are the most common organisms causing skin and
soft tissue infections (SSTIs).
Skin and Soft Tissue Infection Treatment Market: Segmentation
The market for skin and soft tissue
infections treatment is analyzed based on the medications used for its
treatment which includes antibiotics and anti-fungal agents.
Traditionally, use of beta-lactam antibiotics has proved to be
beneficial against various skin and soft tissue infections. However,
with rising use of these traditional medications has led to resistance
of these bacteria against the beta-lactam antibiotics.
Moreover, new strains of infectious
bacteria urge the need for development of new therapies. Consequently
physicians have started using the third-generation antibiotics such as
cephalosporins, fluoroquinolones or extended-spectrum agents such as
amoxicillin and clavulanic acid. The selection of an appropriate drug
depends on the causative microorganism. Besides medications, imaging
tools and surgical methods are also practiced for the treatment of skin
and soft tissue infections (SSTIs).
Skin and Soft Tissue Infection Treatment Market: Key Trends
The rising incidence of
Methicillin-resistant Staphylococcus aureus (MRSA) infections has
resulted in the need for new therapies to combat the serious skin and
soft tissue infections. In addition, new product developments will drive
the skin and soft tissue infections treatment market. Recently, in
February 2014, Cubist Pharmaceuticals, Inc. announced that its Marketing
Authorization Application (MAA) for investigational candidate tedizolid
phosphate has been accepted by the European Medicines Agency (EMA) for
review. With a decision expected from the European Commission (EC)
during the first half of 2015, the company seeks to market its new
product for the treatment of skin and soft tissue infections.
Prior to EMA, the U.S. FDA accepted
company’s New Drug Application (NDA) for review and the company had also
planned for submitting a New Drug Submission (NDS) in Canada in 2014
for tedizolid intended for the treatment of skin and soft tissue
infections. Moreover, in December 2013, Durata Therapeutics, Inc.
announced the acceptance of its Marketing Authorization Application
(MAA) for dalbavancin, intended for the treatment of skin and soft
tissue infections, by the European Medicines Agency (EMA) for review.
The Infectious Diseases Society of
America has recently released guidelines for the diagnosis and
management of skin and soft tissue infections (SSTIs). This practice
guideline is to guide the physicians in proper diagnosis and efficient
treatment of the skin and soft tissue infections and avoid serious
consequences. Based on geography, the skin and soft tissue infections
treatment market is analyzed into North America, Europe, Asia-Pacific
and Rest of the World.
Skin and Soft Tissue Infection Treatment Market: Key Players
Some of the companies engaged in the
development of skin and soft tissue infection (SSTI) treatment
medications include Cubist Pharmaceuticals, Inc., Wockhardt Limited,
Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and
Melinta Therapeutics Inc.
The report offers a comprehensive
evaluation of the market. It does so via in-depth insights,
understanding market evolution by tracking historical developments, and
analyzing the present scenario and future projections based on
optimistic and likely scenarios. Each research report serves as a
repository of analysis and information for every facet of the market,
including but not limited to: Regional markets, technology developments,
types, applications, and the competitive landscape.
No comments:
Post a Comment